Legend Biotech Corp ADR (NASDAQ: LEGN) closed the day trading at $50.12 down -3.07% from the previous closing price of $51.71. On the day, 2695726 shares were traded.
Ratios:
For a better understanding of LEGN, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.83 and its Current Ratio is at 6.92. In the meantime, Its Debt-to-Equity ratio is 0.26 whereas as Long-Term Debt/Eq ratio is at 0.26.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on April 03, 2024, initiated with a Overweight rating and assigned the stock a target price of $82.
On March 13, 2024, Raymond James started tracking the stock assigning a Outperform rating and target price of $86.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 31.97 while its Price-to-Book (P/B) ratio in mrq is 7.29.
Stock Price History:
Over the past 52 weeks, LEGN has reached a high of $77.32, while it has fallen to a 52-week low of $51.07.
Shares Statistics:
A total of 181.91M shares are outstanding, with a floating share count of 180.50M. Insiders hold about 0.78% of the company’s shares, while institutions hold 46.94% stake in the company.
Earnings Estimates
Current recommendations for the stock of the company come from 6 analysts. On average, analysts expect EPS of -$0.35 for the current quarter, with a high estimate of -$0.08 and a low estimate of -$0.75, while EPS last year was -$0.68. The consensus estimate for the next quarter is -$0.46, with high estimates of -$0.09 and low estimates of -$0.77.
Analysts are recommending an EPS of between -$0.5 and -$2.73 for the fiscal current year, implying an average EPS of -$1.52. EPS for the following year is -$0.65, with 9 analysts recommending between $0.42 and -$1.71.
Revenue Estimates
11 analysts predict $156.63M in revenue for the current quarter. It ranges from a high estimate of $202.5M to a low estimate of $80M. As of the current estimate, Legend Biotech Corp ADR’s year-ago sales were $36.34M, an estimated increase of 331.10% from the year-ago figure. For the next quarter, 11 analysts are estimating revenue of $134.28M, an increase of 83.10% less than the figure of $331.10% in the same quarter last year. There is a high estimate of $209.8M for the next quarter, whereas the lowest estimate is $85M.
A total of 17 analysts have provided revenue estimates for LEGN’s current fiscal year. The highest revenue estimate was $701.9M, while the lowest revenue estimate was $450M, resulting in an average revenue estimate of $590.64M. In the same quarter a year ago, actual revenue was $285.14M, up 107.10% from the average estimate. Based on 16 analysts’ estimates, the company’s revenue will be $1.09B in the next fiscal year. The high estimate is $1.53B and the low estimate is $847.99M. The average revenue growth estimate for next year is up 85.20% from the average revenue estimate for this year.
